
    
      For the renal and hepatic subjects, following the screening visit, eligible subjects will
      return to the study site on Study Day 0 and remain at the site for 2 nights and 2 days. Study
      drug administration will occur on Study Day 1. Subjects will be discharged on Study Day 2
      after the last blood sample has been collected. Subjects will return 7 ± 3 days after dosing
      with study drug to have final safety assessments performed. For the healthy subjects,
      following the screening visit, eligible subjects will return to the study site on Study Day 0
      and remain at the site for 3 nights and 3 days. Study drug administration will occur on Study
      Day 1 and Study Day 2. Subjects will be discharged on Study Day 3 after the last blood sample
      has been collected. Subjects will return 7 ± 3 days after receiving the last dose of study
      drug to have final safety assessments performed.
    
  